These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 11156542)

  • 1. UVA-1 cold light treatment of SLE: a double blind, placebo controlled crossover trial.
    Polderman MC; Huizinga TW; Le Cessie S; Pavel S
    Ann Rheum Dis; 2001 Feb; 60(2):112-5. PubMed ID: 11156542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of UVA-1 cold light as an adjuvant therapy for systemic lupus erythematosus.
    Polderman MC; le Cessie S; Huizinga TW; Pavel S
    Rheumatology (Oxford); 2004 Nov; 43(11):1402-4. PubMed ID: 15304672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ultraviolet-A1 (340-400 nm) irradiation therapy in systemic lupus erythematosus.
    McGrath H; Martínez-Osuna P; Lee FA
    Lupus; 1996 Aug; 5(4):269-74. PubMed ID: 8869897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vitamin D Supplementation in Adolescents and Young Adults With Juvenile Systemic Lupus Erythematosus for Improvement in Disease Activity and Fatigue Scores: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Lima GL; Paupitz J; Aikawa NE; Takayama L; Bonfa E; Pereira RM
    Arthritis Care Res (Hoboken); 2016 Jan; 68(1):91-8. PubMed ID: 25988278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus.
    Szepietowski JC; Nilganuwong S; Wozniacka A; Kuhn A; Nyberg F; van Vollenhoven RF; Bengtsson AA; Reich A; de Vries DE; van Hartingsveldt B; Robinson DW; Gordon R; Hsu B
    Arthritis Rheum; 2013 Oct; 65(10):2661-71. PubMed ID: 23896980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial.
    Chang DM; Lan JL; Lin HY; Luo SF
    Arthritis Rheum; 2002 Nov; 46(11):2924-7. PubMed ID: 12428233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.
    Stohl W; Schwarting A; Okada M; Scheinberg M; Doria A; Hammer AE; Kleoudis C; Groark J; Bass D; Fox NL; Roth D; Gordon D
    Arthritis Rheumatol; 2017 May; 69(5):1016-1027. PubMed ID: 28118533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of melatonin supplementation on serum oxidative stress markers and disease activity in systemic lupus erythematosus patients: A randomised, double-blind, placebo-controlled trial.
    Nabatian-Asl M; Ghorbanihaghjo A; Malek Mahdavi A; Khabbazi A; Hajialilo M; Ghojazadeh M
    Int J Clin Pract; 2021 Jul; 75(7):e14246. PubMed ID: 33877728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Testosterone patches in the management of patients with mild/moderate systemic lupus erythematosus.
    Gordon C; Wallace DJ; Shinada S; Kalunian KC; Forbess L; Braunstein GD; Weisman MH
    Rheumatology (Oxford); 2008 Mar; 47(3):334-8. PubMed ID: 18238794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus.
    Ginzler EM; Wallace DJ; Merrill JT; Furie RA; Stohl W; Chatham WW; Weinstein A; McKay JD; McCune WJ; Zhong ZJ; Freimuth WW; Petri MA;
    J Rheumatol; 2014 Feb; 41(2):300-9. PubMed ID: 24187095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study.
    Furie RA; Leon G; Thomas M; Petri MA; Chu AD; Hislop C; Martin RS; Scheinberg MA;
    Ann Rheum Dis; 2015 Sep; 74(9):1667-75. PubMed ID: 24748629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of creatine supplementation in childhood-onset systemic lupus erythematosus: a randomized, double-blind, placebo-controlled, crossover trial.
    Hayashi AP; Solis MY; Sapienza MT; Otaduy MC; de Sá Pinto AL; Silva CA; Sallum AM; Pereira RM; Gualano B
    Lupus; 2014 Dec; 23(14):1500-11. PubMed ID: 25135060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bromocriptine in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled study.
    Alvarez-Nemegyei J; Cobarrubias-Cobos A; Escalante-Triay F; Sosa-Muñoz J; Miranda JM; Jara LJ
    Lupus; 1998; 7(6):414-9. PubMed ID: 9736326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controlled trial with chloroquine diphosphate in systemic lupus erythematosus.
    Meinão IM; Sato EI; Andrade LE; Ferraz MB; Atra E
    Lupus; 1996 Jun; 5(3):237-41. PubMed ID: 8803897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus.
    Petri MA; Mease PJ; Merrill JT; Lahita RG; Iannini MJ; Yocum DE; Ginzler EM; Katz RS; Gluck OS; Genovese MC; Van Vollenhoven R; Kalunian KC; Manzi S; Greenwald MW; Buyon JP; Olsen NJ; Schiff MH; Kavanaugh AF; Caldwell JR; Ramsey-Goldman R; St Clair EW; Goldman AL; Egan RM; Polisson RP; Moder KG; Rothfield NF; Spencer RT; Hobbs K; Fessler BJ; Calabrese LH; Moreland LW; Cohen SB; Quarles BJ; Strand V; Gurwith M; Schwartz KE
    Arthritis Rheum; 2004 Sep; 50(9):2858-68. PubMed ID: 15452837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of raloxifene on disease activity and vascular biomarkers in patients with systemic lupus erythematosus: subgroup analysis of a double-blind randomized controlled trial.
    Mok CC; Ying SK; Ma KM; Wong CK
    Lupus; 2013 Dec; 22(14):1470-8. PubMed ID: 24113197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Placebo-controlled randomized clinical trial of fish oil's impact on fatigue, quality of life, and disease activity in Systemic Lupus Erythematosus.
    Arriens C; Hynan LS; Lerman RH; Karp DR; Mohan C
    Nutr J; 2015 Aug; 14():82. PubMed ID: 26283629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus.
    Carneiro JR; Sato EI
    J Rheumatol; 1999 Jun; 26(6):1275-9. PubMed ID: 10381042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial.
    Kalunian KC; Davis JC; Merrill JT; Totoritis MC; Wofsy D;
    Arthritis Rheum; 2002 Dec; 46(12):3251-8. PubMed ID: 12483729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea.
    Zhang F; Bae SC; Bass D; Chu M; Egginton S; Gordon D; Roth DA; Zheng J; Tanaka Y
    Ann Rheum Dis; 2018 Mar; 77(3):355-363. PubMed ID: 29295825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.